Uterine sarcomas

Pautier, Patricia

doi:10.1007/s10269-006-0545-5

Cited by 10 publications

(27 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Cependant, à l'heure actuelle, la plupart des auteurs s'accordent à reconnaître une place systématique à l'irradiation pelvienne dans les sarcomes utérins afin d'assurer le contrôle local [1,2,18].…”

Section: Quelle Est La Place De La Radiothérapie ?unclassified

See 1 more Smart Citation

Hystérectomies pour léiomyomes présumés : la crainte du léiomyosarcome doit-elle faire appréhender la voie d’abord chirurgicale autre que laparotomique ?

Leung¹,

Terzibachian²,

Gay³

et al. 2009

Gynécologie Obstétrique & Fertilité

View full text Add to dashboard Cite

Section: Quelle Est La Place De La Radiothérapie ?unclassified

“…Cette tumeur est caractérisée par un mauvais pronostic avec un taux de survie à cinq ans de l'ordre de 30 % [1,2].…”

Section: Introductionunclassified

Hystérectomies pour léiomyomes présumés : la crainte du léiomyosarcome doit-elle faire appréhender la voie d’abord chirurgicale autre que laparotomique ?

Leung¹,

Terzibachian²,

Gay³

et al. 2009

Gynécologie Obstétrique & Fertilité

View full text Add to dashboard Cite

“…Especially targeted therapies with anti-angiogenic remain good candidates for the treatment of sarcomas and are being evaluated in this disease; despite the negativity of the phase II trial of Thalidomide [24,25].…”

Section: Discussionmentioning

confidence: 99%

Management of Uterine Sarcomas

Naim¹,

Bouchbika²,

Aksim³

et al. 2012

JCT

View full text Add to dashboard Cite

Uterine sarcomas are rare malignant tumors characterized by a great clinical and histopathological diversity. The aim of this work is to analyze the difficulties of diagnosis, therapeutic and prognosis posed by these tumors. Thirty-seven patients with uterine sarcoma, collected in the service Radiotherapy and Oncology, University Ibn Rochd of Casablanca between January 2000 and December 2007 were included in this study retrospective. The average patient age was 50 years (17 -76). The bleeding was present in all patients, isolated in 54% of cases associated with pelvic pain in 24.6% and a mass abdomino-pelvic in seven patients. The average time of evolution was 10 months. The main histological type was found leiomyosarcoma. Twenty four patients in our series underwent total hysterectomy without annexial conservation. The surgery R0 was obtained in 43% of cases. The sarcomas were classified as stage IV in 51.4%. Adjuvant radiotherapy was indicated in 13 patients. After a mean of 20 months, half of patients evaluable presented a local relapse and/or metastatic, the third of cases were tumor progression while complete remission was maintained in 18.5% of cases. Uterine sarcomas are rare malignant mesenchymal tumor, which often occur in women after menopause. The main prognostic factors are hormonal status of the patient, stage clinical, histological type, histological grade and quality surgical excision. The management of uterine sarcomas is multidisciplinary, based mainly on surgery remains the only means of cure. Adjuvant radiotherapy allows decreased risk of local recurrence, with no impact on survival achieved at best 30% at 5 years. The role of chemotherapy remains confirm.

show abstract

“…Seul le sous-groupe des sarcomes du stroma endométrial de bas grade présente une survie prolongée [13,49].…”

Section: Discussionunclassified

“…L'index mitotique semble être un facteur histologique pronostique dans le groupe de léiomyosarcomes [14,49,50]. L'importance de l'infiltration myométriale constitue un facteur pronostique dans le groupe des carcinosarcomes [49,50].…”

Section: Discussionunclassified